BridgeBio Pharma, Inc.: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 3, 2022 and accepted by EDGAR at Nov 3, 2022, 16:33 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-07-01 to 2022-09-30 | $338.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2022-01-01 to 2022-09-30 | $75.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2022-07-01 to 2022-09-30 | $92.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-01-01 to 2022-09-30 | $308.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-07-01 to 2022-09-30 | $31.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-01-01 to 2022-09-30 | $111.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | −$129.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | −$383.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-07-01 to 2022-09-30 | $19.8m | us-gaap:InterestExpense |
| Interest expense | 9 months2022-01-01 to 2022-09-30 | $60.4m | us-gaap:InterestExpense |
| Income tax | 3 months2022-07-01 to 2022-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-01-01 to 2022-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-07-01 to 2022-09-30 | −$140.2m | us-gaap:ProfitLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | −$344.1m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | −$0.93 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | −$2.34 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | −$0.93 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | −$2.34 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 147,937,817 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 146,842,453 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | −$326.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-01-01 to 2022-09-30 | $4.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-09-30 | $483.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $642.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $728.7m | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $119.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $1.86bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-09-30 | −$1.14bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-22-021936. Last ingested by Listed: Nov 12, 2026, 17:56 ET. Listed shows no prices and gives no investment advice.